Allarity presents new Phase 2 clinical data for Stenoparib

Allarity (ALLR) Therapeutics, a Phase 2 clinical-stage pharmaceutical company dedicated to developing stenoparib, a differentiated, dual PARP and WNT pathway inhibitor, announced that Dr Jeremy Graff, President and Chief Development Officer for Allarity Therapeutics, presented new and updated clinical data from the ongoing Phase 2 clinical trial in advanced ovarian cancer patients at the American Association for Cancer Research (AACR) 7th Biennial Special Conference on Ovarian Cancer, held September 19-21, 2025, at the Grand Hyatt Denver in Denver, Colorado. The presentation showcased the first Kaplan-Meier analysis for median Overall Survival from the Company’s ongoing Phase 2 trial that enrolled patients with advanced ovarian cancer, all of whom had either platinum-resistant or refractory disease and had tumors showing a Stenoparib-specific Drug Response Predictor score above 50. Notably, these data provide the first evidence that stenoparib, when given twice daily, may extend patient survival. The mOS has not been formally reached yet and now exceeds 25 months. Two patients actively remain on therapy now more than 24 months, with one of these two patients carrying a wild-type BRCA gene-a genetic background that typically precludes benefit from PARP inhibitors. Notably, one patient with primary platinum-refractory disease remains alive more than two years after enrollment-a clinical outcome that is highly uncommon in this population.